Healthcare Resource Utilization in Patients With Hidradenitis Suppurativa Using Adelphi Real-World Data From EU5 and US
Author(s)
Tanja Tran, PhD1, Jeremy Schafer, PharmD, MBA1, Michael Frank Mørup, MSc2, Bartosz Lukowski, PhD3, Aaron Keal, MSc4, Aijing Shang, PhD5.
1UCB, Brussels, Belgium, 2UCB, Copenhagen, Denmark, 3Vedim/UCB, Warsaw, Poland, 4Adelphi Real World, Bollington, United Kingdom, 5UCB, Basel, Switzerland.
1UCB, Brussels, Belgium, 2UCB, Copenhagen, Denmark, 3Vedim/UCB, Warsaw, Poland, 4Adelphi Real World, Bollington, United Kingdom, 5UCB, Basel, Switzerland.
OBJECTIVES: Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with debilitating symptoms, requiring frequent healthcare encounters.1 This study describes healthcare resource utilisation (HCRU) in EU5 (France, Germany, Italy, Spain, UK) and the United States (US).
METHODS: Data were drawn from the Adelphi Real-World HS Disease-Specific Programme™, a cross-sectional survey with retrospective data collection in EU5 and US (March 2024-March 2025). Data included HS severity (physician-assessed) and HS-related HCRU. Frequencies (%) of biologic use, hospitalisation and surgery in 12 months prior to the survey were assessed. Analyses were descriptive.
RESULTS: Survey data of 1,910 patients with HS (mean age 34.9 years; 55% female) were collected. At collection, 63%, 30% and 6% of patients had mild, moderate and severe disease, respectively. Biologics were being used by 741 (39%) patients (France: 47%; Germany: 22%; Italy: 33%; Spain: 52%; UK: 40%; US: 40%), and by 32%, 47% and 72% of patients with mild, moderate and severe HS, respectively. Mean time on biologics at collection was 14.5 months (SD:16.8).
In 12 months before data collection, 203 (11%) patients had been hospitalised (HS mild: 8%; moderate: 13%; severe: 23%) with a mean of 1.7 (SD:1.2) hospitalisations. Surgery was received by 243 (13%) patients (HS mild: 10%; moderate: 17%; severe: 20%); incision/drainage (60%) was most common, then local/limited excision (25%), deroofing (12%) and wide excision (12%). Of patients using biologics, 15% had hospitalisations (biologic <6 months: 18%; ≥6 months: 14%) and 14% received surgery (biologic <6 months: 24%; ≥6 months: 10%).
CONCLUSIONS: HCRU is high in patients with moderate to severe HS. In patients using biologics, HCRU aligned with the overall sample and reduced in patients with ≥6 months biologic treatment relative to <6 months. Despite recent advances in HS care, these real-world data suggest that HCRU-related disease burden is still evident in HS.
REFERENCES
1. Garg A. AJCD 2023;24:977-990.
METHODS: Data were drawn from the Adelphi Real-World HS Disease-Specific Programme™, a cross-sectional survey with retrospective data collection in EU5 and US (March 2024-March 2025). Data included HS severity (physician-assessed) and HS-related HCRU. Frequencies (%) of biologic use, hospitalisation and surgery in 12 months prior to the survey were assessed. Analyses were descriptive.
RESULTS: Survey data of 1,910 patients with HS (mean age 34.9 years; 55% female) were collected. At collection, 63%, 30% and 6% of patients had mild, moderate and severe disease, respectively. Biologics were being used by 741 (39%) patients (France: 47%; Germany: 22%; Italy: 33%; Spain: 52%; UK: 40%; US: 40%), and by 32%, 47% and 72% of patients with mild, moderate and severe HS, respectively. Mean time on biologics at collection was 14.5 months (SD:16.8).
In 12 months before data collection, 203 (11%) patients had been hospitalised (HS mild: 8%; moderate: 13%; severe: 23%) with a mean of 1.7 (SD:1.2) hospitalisations. Surgery was received by 243 (13%) patients (HS mild: 10%; moderate: 17%; severe: 20%); incision/drainage (60%) was most common, then local/limited excision (25%), deroofing (12%) and wide excision (12%). Of patients using biologics, 15% had hospitalisations (biologic <6 months: 18%; ≥6 months: 14%) and 14% received surgery (biologic <6 months: 24%; ≥6 months: 10%).
CONCLUSIONS: HCRU is high in patients with moderate to severe HS. In patients using biologics, HCRU aligned with the overall sample and reduced in patients with ≥6 months biologic treatment relative to <6 months. Despite recent advances in HS care, these real-world data suggest that HCRU-related disease burden is still evident in HS.
REFERENCES
1. Garg A. AJCD 2023;24:977-990.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
EE507
Topic
Economic Evaluation, Real World Data & Information Systems
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
Sensory System Disorders (Ear, Eye, Dental, Skin)